Eli Lilly And Co (NYSE:LLY) was upgraded by stock analysts at TheStreet from a “c+” rating to a “b” rating in a note issued to investors on Friday.
Several other analysts also recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $91.00 price target on shares of Eli Lilly And Co in a research note on Friday, March 23rd. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research note on Monday, April 9th. BMO Capital Markets reaffirmed a “sell” rating and set a $74.00 price target on shares of Eli Lilly And Co in a research note on Wednesday, April 4th. HC Wainwright reaffirmed a “buy” rating on shares of Eli Lilly And Co in a research note on Wednesday, April 18th. Finally, Credit Suisse Group set a $80.00 price target on shares of Eli Lilly And Co and gave the company a “hold” rating in a research note on Sunday, April 22nd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $94.00.
Eli Lilly And Co opened at $85.86 on Friday, MarketBeat.com reports. The company has a quick ratio of 1.01, a current ratio of 1.41 and a debt-to-equity ratio of 0.64. Eli Lilly And Co has a fifty-two week low of $73.69 and a fifty-two week high of $89.09. The company has a market cap of $92.62 billion, a PE ratio of 20.06, a P/E/G ratio of 1.48 and a beta of 0.25.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 24th. The company reported $1.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.13 by $0.21. Eli Lilly And Co had a net margin of 4.82% and a return on equity of 35.37%. The firm had revenue of $5.70 billion during the quarter, compared to the consensus estimate of $5.51 billion. During the same quarter in the previous year, the firm posted $0.98 earnings per share. The company’s revenue was up 9.0% on a year-over-year basis. sell-side analysts predict that Eli Lilly And Co will post 5.15 EPS for the current year.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 180,000 shares of Eli Lilly And Co stock in a transaction on Friday, June 15th. The shares were sold at an average price of $86.65, for a total value of $15,597,000.00. Following the transaction, the insider now directly owns 122,050,804 shares of the company’s stock, valued at $10,575,702,166.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Susan Mahony sold 5,165 shares of Eli Lilly And Co stock in a transaction on Friday, April 13th. The stock was sold at an average price of $80.14, for a total transaction of $413,923.10. Following the completion of the transaction, the senior vice president now directly owns 45,652 shares in the company, valued at $3,658,551.28. The disclosure for this sale can be found here. Insiders sold 987,464 shares of company stock worth $82,748,955 over the last ninety days. Corporate insiders own 0.11% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Park National Corp OH grew its holdings in Eli Lilly And Co by 20.8% in the second quarter. Park National Corp OH now owns 103,115 shares of the company’s stock worth $8,799,000 after purchasing an additional 17,766 shares during the last quarter. Brown Advisory Inc. grew its holdings in Eli Lilly And Co by 66.6% in the first quarter. Brown Advisory Inc. now owns 136,561 shares of the company’s stock worth $10,565,000 after purchasing an additional 54,577 shares during the last quarter. Avalon Advisors LLC grew its holdings in Eli Lilly And Co by 0.4% in the first quarter. Avalon Advisors LLC now owns 273,915 shares of the company’s stock worth $21,193,000 after purchasing an additional 965 shares during the last quarter. Mount Yale Investment Advisors LLC purchased a new position in Eli Lilly And Co in the first quarter worth $6,248,000. Finally, Rikoon Group LLC grew its holdings in Eli Lilly And Co by 30.5% in the first quarter. Rikoon Group LLC now owns 4,274 shares of the company’s stock worth $323,000 after purchasing an additional 999 shares during the last quarter. 76.03% of the stock is currently owned by institutional investors and hedge funds.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.